Clinical Trial Update: Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated a regimen of radiation therapy with bevacizumab, paclitaxel, and carboplatin in patients with unresectable Stage IIIB or Stage IV n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenosquamous Lung Carcinoma
• Non-small Cell Lung Cancer
• Squamous Cell Lung Cancer
• Stage Iiib Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenosquamous Cell Lung Cancer, Drug/Agent Toxicity by Tissue/Organ | Phase 2 | Status: COMPLETED